No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Epredia Announces the U.S. Launch of SlideMate Laser | Provides State-of-the-Art Precision Slide Printing for Pathology Laboratories

Editor: What To Know

  • SlideMate Laser provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides that pathologists use in the cancer diagnostics workflow.
  • This technology can embed up to 50 characters in a barcode on each slide, compared to 23 characters with traditional thermal transfer and ink jet technologies, helping to improve both patient sample tracking and efficiency.
  • sales of SlideMate™ Laser, the newest addition to the company's SlideMate portfolio of slide printers, which are used in pathology laboratories to identify and help track tissue samples.

SlideMate Laser

Epredia, a global leader in precision cancer diagnostics, today announced that it has launched U.S. sales of SlideMate™ Laser, the newest addition to the company’s SlideMate portfolio of slide printers, which are used in pathology laboratories to identify and help track tissue samples.

Design

Epredia has designed SlideMate Laser for clinical laboratories of any size looking to improve sample traceability. SlideMate Laser provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides that pathologists use in the cancer diagnostics workflow. This technology can embed up to 50 characters in a barcode on each slide, compared to 23 characters with traditional thermal transfer and ink jet technologies, helping to improve both patient sample tracking and efficiency.

Enhances Laboratory Efficiency

SlideMate Laser also enhances laboratory efficiency by optimizing the slide movements through the printer and reducing potential downtime compared to thermal transfer and ink jet printers. Without the need to purchase, ink, bulb or tape for slide printers, users can expect lower operational costs. With both on-demand and batch printing options, SlideMate Laser can integrate into a range a workflows. The laser printer’s software is easy to use and can be directly interfaced to a Laboratory Information System.

SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. Epredia also offers the specialized slides designed for use with SlideMate Laser to help laboratories make a smooth transition to precision laser printing. This includes non-adhesion slides with Superfrost™ technology and adhesion slides with Superfrost PLUS™ technology to maximize tissue adherence. Slides are available in five colors, which laboratories can use to coordinate downstream activities.

Manufactured In San Benedetto del Tronto, Italy

SlideMate Laser is manufactured by Fa-Tech Diagnostics Italia SRL, located in San Benedetto del Tronto, Italy which Epredia’s parent company PHC Holdings Corporation acquired in 2021. All SlideMate Laser slides are manufactured by Epredia in the U.S. in its facility in Portsmouth, New Hampshire.

Other Biotechnology News

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

The Future of Biotechnology: Insights Into Cutting-Edge Developments

The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.

Advancing Patient Care: LyGenesis Doses First Patient in Phase 2a Trial

"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy